Repligen Corporation $RGEN Position Raised by Fred Alger Management LLC

Key Points

• Fred Alger Management LLC increased its stake in Repligen Corporation by 21.6% in Q1, now holding 437,037 shares valued at approximately $55.6 million.
• Various institutional investors have also boosted their positions in Repligen, with 97.64% of the stock owned by such entities.
• Repligen's recent quarterly report showed earnings per share of $0.37, missing estimates, but revenue increased by 14.8% year-over-year to $182.37 million.

Fred Alger Management LLC raised its position in Repligen Corporation (NASDAQ:RGEN - Free Report) by 21.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 437,037 shares of the biotechnology company's stock after acquiring an additional 77,530 shares during the quarter. Fred Alger Management LLC owned 0.78% of Repligen worth $55,609,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. KBC Group NV grew its position in Repligen by 14.9% in the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock valued at $324,000 after acquiring an additional 329 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in Repligen in the first quarter valued at approximately $132,000. XTX Topco Ltd grew its position in Repligen by 34.2% in the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock valued at $1,646,000 after acquiring an additional 3,295 shares in the last quarter. GAMMA Investing LLC grew its position in Repligen by 40.1% in the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock valued at $122,000 after acquiring an additional 274 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its position in Repligen by 233.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock valued at $1,172,000 after acquiring an additional 6,448 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Stock Performance

RGEN traded down $5.97 during trading hours on Friday, hitting $113.54. 707,503 shares of the stock were exchanged, compared to its average volume of 665,349. The stock has a 50-day simple moving average of $120.73 and a 200-day simple moving average of $127.78. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The stock has a market cap of $6.39 billion, a price-to-earnings ratio of -454.14, a price-to-earnings-growth ratio of 2.20 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter last year, the business earned $0.40 earnings per share. The business's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on RGEN. Evercore ISI decreased their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Wednesday, September 3rd. Royal Bank Of Canada reissued an "outperform" rating and set a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 price target for the company in a research report on Tuesday, July 22nd. Finally, Jefferies Financial Group decreased their price target on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a research report on Friday. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $166.67.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares of the company's stock, valued at $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.